- Home
- OCUP vs NTRB Comparison
OCUP vs NTRB Comparison
Compare OCUP & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUP
- NTRB
- Stock Information
- Founded
- OCUP 2018
- NTRB 2016
- Country
- OCUP United States
- NTRB United States
- Employees
- OCUP N/A
- NTRB N/A
- Industry
- OCUP Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- OCUP Health Care
- NTRB Health Care
- Exchange
- OCUP Nasdaq
- NTRB Nasdaq
- Market Cap
- OCUP 53.1M
- NTRB 49.2M
- IPO Year
- OCUP N/A
- NTRB N/A
- Fundamental
- Price
- OCUP $1.27
- NTRB $6.88
- Analyst Decision
- OCUP Strong Buy
- NTRB
- Analyst Count
- OCUP 3
- NTRB 0
- Target Price
- OCUP $18.67
- NTRB N/A
- AVG Volume (30 Days)
- OCUP 92.8K
- NTRB 48.8K
- Earning Date
- OCUP 11-11-2024
- NTRB 09-03-2024
- Dividend Yield
- OCUP N/A
- NTRB N/A
- EPS Growth
- OCUP N/A
- NTRB N/A
- EPS
- OCUP N/A
- NTRB N/A
- Revenue
- OCUP $16,449,000.00
- NTRB $1,803,816.00
- Revenue This Year
- OCUP N/A
- NTRB N/A
- Revenue Next Year
- OCUP $258.69
- NTRB N/A
- P/E Ratio
- OCUP N/A
- NTRB N/A
- Revenue Growth
- OCUP N/A
- NTRB N/A
- 52 Week Low
- OCUP $1.15
- NTRB $1.53
- 52 Week High
- OCUP $3.50
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- OCUP 44.79
- NTRB 64.91
- Support Level
- OCUP $1.24
- NTRB $5.70
- Resistance Level
- OCUP $1.34
- NTRB $7.74
- Average True Range (ATR)
- OCUP 0.08
- NTRB 0.59
- MACD
- OCUP 0.00
- NTRB 0.07
- Stochastic Oscillator
- OCUP 12.00
- NTRB 59.81
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.